Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly, accusing Lilly of misleading advertising about their weight-loss drug efficacy. Novo argues that Lilly's ads compare Lilly's Zepbound to an older, lower-dose version of Novo's Wegovy, ignoring Novo's newer, more effective 7.2 mg Wegovy dose. The dispute highlights fierce competition in the GLP-1 weight-loss drug market, with Novo promoting its new Wegovy pill and Lilly defending its advertising as truthful. Market shares are shifting as both companies compete aggressively in this growing sector.
Canada has enacted retaliatory tariffs on $20 billion worth of U.S. goods, including steel, aluminum, dairy, and electronics, escalating an 18-month trade dispute. These tariffs range from 15% to 50% and affect key sectors, putting pressure on North ...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four key metrics. Since its inception, it has delivered an average return of 14.89%, marginally beating SCHD's 14....
